BIIB Biogen Inc

Price (delayed)

$299.69

Market cap

$44.66B

P/E Ratio

23.52

Dividend/share

N/A

EPS

$12.74

Enterprise value

$50.55B

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. ...

Highlights
Biogen's debt has decreased by 2.6% YoY
The company's quick ratio fell by 23% YoY but it rose by 2.7% QoQ
Biogen's net income has shrunk by 68% YoY and by 36% QoQ
The EPS has plunged by 63% YoY and by 34% from the previous quarter

Key stats

What are the main financial stats of BIIB
Market
Shares outstanding
149.03M
Market cap
$44.66B
Enterprise value
$50.55B
Valuations
Price to earnings (P/E)
23.52
Price to book (P/B)
4.2
Price to sales (P/S)
3.84
EV/EBIT
27.97
EV/EBITDA
16.59
EV/Sales
4.32
Earnings
Revenue
$11.7B
EBIT
$1.81B
EBITDA
$3.05B
Free cash flow
$2.46B
Per share
EPS
$12.74
Free cash flow per share
$16.44
Book value per share
$71.42
Revenue per share
$78.14
TBVPS
$109.03
Balance sheet
Total assets
$24.47B
Total liabilities
$13.26B
Debt
$7.63B
Equity
$10.75B
Working capital
$3.84B
Liquidity
Debt to equity
0.71
Current ratio
2.15
Quick ratio
1.54
Net debt/EBITDA
1.93
Margins
EBITDA margin
26%
Gross margin
83.9%
Net margin
16.4%
Operating margin
18.9%
Efficiency
Return on assets
7.8%
Return on equity
17.9%
Return on invested capital
9.8%
Return on capital employed
8.6%
Return on sales
15.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BIIB stock price

How has the Biogen stock price performed over time
Intraday
0.16%
1 week
-0.15%
1 month
-12.75%
1 year
8.43%
YTD
22.39%
QTD
-13.45%

Financial performance

How have Biogen's revenue and profit performed over time
Revenue
$11.7B
Gross profit
$9.82B
Operating income
$2.22B
Net income
$1.92B
Gross margin
83.9%
Net margin
16.4%
BIIB's operating income has dropped by 70% year-on-year and by 40% since the previous quarter
Biogen's net income has shrunk by 68% YoY and by 36% QoQ
Biogen's operating margin has plunged by 63% YoY and by 36% from the previous quarter
Biogen's net margin has plunged by 60% YoY and by 31% from the previous quarter

Growth

What is Biogen's growth rate over time

Valuation

What is Biogen stock price valuation
P/E
23.52
P/B
4.2
P/S
3.84
EV/EBIT
27.97
EV/EBITDA
16.59
EV/Sales
4.32
The EPS has plunged by 63% YoY and by 34% from the previous quarter
The P/E is 55% above the last 4 quarters average of 15.2 and 54% above the 5-year quarterly average of 15.3
BIIB's price to book (P/B) is 4.5% lower than its 5-year quarterly average of 4.4 but 2.4% higher than its last 4 quarters average of 4.1
The equity has contracted by 4.9% YoY
Biogen's revenue has decreased by 19% YoY and by 7% from the previous quarter
The stock's price to sales (P/S) is 11% less than its 5-year quarterly average of 4.3 but 10% more than its last 4 quarters average of 3.5

Efficiency

How efficient is Biogen business performance
The ROIC has plunged by 76% YoY and by 52% from the previous quarter
The ROS has plunged by 69% YoY and by 48% from the previous quarter
Biogen's return on assets has shrunk by 65% YoY and by 36% QoQ
The ROE has plunged by 61% YoY and by 35% from the previous quarter

Dividends

What is BIIB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIIB.

Financial health

How did Biogen financials performed over time
The total assets is 85% more than the total liabilities
The company's quick ratio fell by 23% YoY but it rose by 2.7% QoQ
The current ratio has contracted by 13% YoY
Biogen's debt is 29% less than its equity
The equity has contracted by 4.9% YoY
The debt to equity has increased by 2.9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.